MarketPulse

immunology

24 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Great Point Partners Doubles Down on Apogee Therapeutics With $28M Position

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Prime Medicine, Inc.

Prime Medicine to Present at Three Major Biotech Conferences in March

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.
PRMEclinical developmentinvestor conference
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis
BenzingaBenzinga··Vandana Singh

Sanofi Shares Slide as Hudson Steps Down; Garijo to Lead Post-AGM

Sanofi CEO Paul Hudson steps down February 17; Belén Garijo takes over post-AGM. Stock fell 4.5% on leadership transition announcement amid vaccine sales decline concerns.
SNYREGNstock declineCEO transition